51 results about "Hep G2" patented technology

The invention relates to the medicine technical field, in particular to saponin compounds of Siraitic acid IIB and Siraitic acid IIC which are extracted and separated from fructus momordicae roots, a method for preparing the same and application thereof in an anti-tumor medicine. The molecular formulas of the two compounds are C40H60O14 and C41H62O15 respectively. By various modern spectral analysis, particularly the application of advanced two-dimensional nuclear magnetic resonance spectrum to comprehensive analysis, the chemical structures of the two compounds are determined. In vitro anti-tumor tests show that the compound Siraitic acid IIB can obviously inhibit lung cancer cells A-549 and liver cancer cells Hep-G2, and the compound Siraitic acid IIC can also obviously inhibit liver cancer cells Hep-G2. The invention provides lead compound for research on a new anti-tumor medicine, and has essential values in comprehensively developing and utilizing fructus momordicae resources.

The invention relates to a phenothiazine compound and a preparation method thereof. The invention further relates the application of the phenothiazine compound in anti-cancer drug preparation and anti-cancer drugs using the compound as the effective component. The phenothiazine compound has the advantages that the compound with broad-spectrum anti-cancer effect is obtained by modifying phenothiazine ternary interlink parent nucleuses, synthesizing method is simple, and high yield is achieved; the phenothiazine compound has certain restraining effect on human breast cancer cells line MCF-7 and human hepatoma cell line Hep-G2, and a new thought is provided to new drugs satisfying clinic requirements.

The invention relates to assessment and fermentation of marine actinomycete WBF9 that is used for producing anti-tumor compound and the separation and purification of the anti-tumor compound and the cytotoxic activity, and pertains to the microscopic organisms medicine filed. Bacterial strain WBF9, which is streptomyces griseorubens that is separated from the sea for the first time, is identified as one of the new bacterial strains of streptomyces griseorubens by traditionally classification and 16SrDNA genetic analysis. Culture medium (glucose: 1 percent, potato: 15 percent, yeast powder: 0.6 percent, calcium chloride: 0.12 percent and natural seawater, pH value 7.2) is applied by the bacterial strain for fermentation, and the compound extracted from the fermentation liquor, which has strong anti-tumor activity and identified as Norharmane by MS and NMR technique, is the first compound that is acquired by separating marine actinomycete. According to the MTT method, the compound is found to have cytotoxicity against four tumor cells: KB, BGC 803, Hep G2 and SGC 7901, and is a potential anti-tumor medicine.

The invention relates to a chlorin and artesunate compound with photosensitive and sound-sensitive activity as well as a preparation method and an application of the compound and belongs to the technical field of chemical medicines. The chlorin and artesunate compound with photosensitive and sound-sensitive activity has different degrees of inhibition effects on human hepatoma cells Hep G2 in in-vitro anti-tumor activity evaluation. The photoactivity and ultrasonic activity are both higher than that of chlorin e6 and artesunate which are used as positive controls. The compound can be used for preparing a photosensitizer and a sound-sensitive agent in photodynamic therapy and sonodynamic therapy methods for tumor therapy.

The invention relates to a hydrophilic chlorin photo-sensitive and sono-sensitive agent with long wavelength and a preparation method and an application thereof, and belongs to the field of chemical medicine. The compound is represented as the following formula described in the description. The compound of hydrophilic chlorin photo-sensitive and sono-sensitive agent with long wavelength has inhibition effects in different degrees on human liver cancer cell Hep G2 in anticancer activity evaluation in vitro. The ratio of photoactivity to dark activity and the ratio of sono-activity to dark activity are much higher than that of hemoporphyrinmonomethyl ether as a positive contrast. The hydrophilic chlorin photo-sensitive and sono-sensitive agent with long wavelength has advantages of low toxicity, high efficiency, treatment wavelength moving towards long wave region and the like. The compound in the invention can be used as an excellent photosensitizer and an excellent sonosensitizer for photodynamic and sonodynamic therapy of tumors.

The invention relates to a method for verifying and fermenting polar marine ray fungi AFN1007 producing antitumor active substance, and the research on the antitumor activity of the zymotic fluid thereof, belonging to the microbial medicine field. The strain AFN1007 is verified to be a novel kind of Streptomyces by the traditional classification and the analysis of 16S rDNA gene of the AFN1007. The compositions of a culture medium by percentage are: 1 percent of soybean flour, 1 percent of tragantine, 0.1 percent of KNO3, 0.05 percent of MgSO4, 0.001 percent of FeSO4, 0.05 percent of NaCl and natural seawater with a pH value between 7.2 and 7.4. The strain is fermented by using the culture medium. The MTT method shows that the zymotic fluid has strong antitumor action on four tumor cells of KB, BGC 803, Hep G2 and Hela and an antitumor compound with a novel structure is expected to be found in the zymotic fluid.

The invention relates to the fields of marine organism and medical technology, and provides an aaptamine alkaloid compound which is obtained by extraction, separation and purification from marine Aaptos aaptos produced in sea areas nearby the Paracel Islands, wherein the chemical structure of the alkaloid compound is as shown in the formula (I) (in the specification). In-vitro activity tests prove that the alkaloid compound has remarkable inhibitory activity on various different tumor cells such as human acute leukemic cells HL60, human chronic leukemic cells K562, human breast cancer cells MCF-7, human nasopharyngeal carcinoma cells KB, human liver cancer cells Hep G2 and human colon cancer cells HT-29, and the alkaloid compound can be used for preparing anti-tumor medicines.

The invention discloses a compound Chinese actinidia root Chinese medicinal composition and a preparation method and application thereof, belonging to the technical field of traditional Chinese medicines. The Chinese medicinal composition is characterized by comprising the following traditional Chinese medicines in parts by weight: 40-80 parts of Chinese actinidia root, 20-40 parts of salvia chinensis, 20-40 parts of herba scutellariae barbatae, 20-40 parts of herba oldenlandiae and 20-40 parts of giant knotweed. The compound Chinese actinidia root Chinese medicinal composition has remarkable proliferation inhibition effects on various cancer cells such as a hepatoma cell line Hep-G2, a lung cancer cell line NCI-H460, a gastric cancer cell line MGC-803, a breast cancer cell line MCF-7, a colon cancer cell line HCT-116 and the like, and can be used for reducing physical and psychological pains of a cancer patient in the chemo-treatment process and solving the problems of difficult and expensive administration.

The invention discloses a vitamin D oxime derivative and a synthetic method and an application thereof. The method comprises the following steps: carrying out an oximation reaction between a compound I and hydroxylamine hydrochloride, thereby obtaining two A cyclic oxime derivatives such as (Z)-3-oxime vitamin D2 and (E)-3-oxime vitamin D2 of the vitamin D2 of different configurations; and enabling a compound 1.2 to react with methoxylamine hydrochloride, thereby obtaining two A cyclic oxime ether derivatives such as (Z)-3-methyl oxime ester vitamin D2 and (E)-3-methyl oxime ester vitamin D2 of the vitamin D2 of different configurations. The four vitamin D oxime derivatives have good effects of inhibiting human hepatoma cells Hep G2 and human breast cancer cells MCF-7 and have potential medicinal values.

This invention characterizes the selective apoptotic activity of specially prepared Alpha 2-HS glycoprotein and fragments thereof. Specifically, Alpha 2-HS glycoprotein which has been overloaded with zinc, as well as fragnents thereof, selectively induce apoptosis in HT-29 (colon cancer), LNCaP (prostate cancer) and Hep G2 (hepatoma) cells while having no effect on CCD 18 Co (normal colon) cells.

The invention relates to the technical field of marine organisms and medicines and provides an aaptamine alkaloid compound extracted, separated and purified from a marine animal aaptos originating from surrounding waters of the Xisha Islands. The chemical structure of the aaptamine alkaloid compound is shown in a formula (I) as shown in the specification. In-vitro activity tests prove that the compound has obvious inhibitory activity on various tumor cells such as human acute leukemic cells HL60, human chronic leukemic cells K562, human breast cancer cells MCF-7, human nasopharyngeal cancer cells KB, human liver cancers Hep G2, human colon cancer cells HT-29 and the like and can be used for preparing antitumor medicines.

The invention discloses a cobalt (II) complex of quinolinone derivative, and a synthesis method and application thereof. The synthesis method of the quinolinone cobalt complex comprises the following steps: weighing cobaltous chloride and a ligand 3-(1H-benzimidazolyl-2-yl)-6-methyl-2(1H)-quinolinone according to the stoichiometric proportion, dissolving in a polar solvent, and carrying out complexing reaction. The research of the in-vitro antitumor activity indicates that the complex has certain proliferation inhibition activity for human cervical cancer cell Hela229, human stomach cancer cell MGC-803, human liver cancer cell strain Hep G2 and BEL-7404 cell strain, and has the maximum activity for human liver cancer cell strain Hep G2. The quinolinone cobalt complex is disclosed as the following formula (I).

The invention belongs to the field of organic chemical synthesis, and discloses cyclobutyl-1-enamine compounds, a preparation method thereof and application of the cyclobutyl-1-enamine compounds in antiviral and antitumor drugs. The compound has a structure of a general formula (I), and EWG is selected from alkyl or aryl substituted sulfonyl; r is selected from alkyl, alkoxy, halogen and nitryl. The preparation method comprises the following steps: heating an alkyne amide raw material to a molten state under thermal driving, and carrying out [2 + 2] cycloaddition reaction among molecules to obtain the polysubstituted cyclobutyl-1-enamine compound. The method has the advantages of easily available raw materials, simple steps, no catalyst, no solvent, high yield and the like. The compound has anti-SARS-CoV-2, 5637, Hela, SW480, Hep G2, A549 and MCF-7 activity, and has a good application prospect in the aspect of treating novel coronavirus, bladder cancer, cervical cancer, colon cancer, liver cancer, lung cancer and breast cancer. (I).

The invention relates to a new carbazole alkaloid represented by the formula (1), and also relates to a preparation method thereof and applications thereof. The alkaloid is characterized in that: crude extracts of an organic solvent of Antipathes dichotcma (Pallas) are extracted with ethyl acetate or chloroform after being suspended on water, an ethyl acetate layer or a chloroform layer is collected for carrying out the normal pressure silica gel column chromatography, the thin-layer chromatography is used for tracing and combination, and a chloroform-acetone solvent system in a volume ratio of 9:1 is used for elution, the collected Rf value is about 0.5 to 0.7, and compositions of ultraviolet absorption exist under the wavelength of 254nm of an ultraviolet lamp, a crude product is gained, and a pure product is obtained through the further purification. The carbazole alkaloid can be used for preparing medicines treating gastric cancers, liver cancers and anti-herpes simplex virus, and has the half inhibition concentration IC50 of 67.38mu g/mL and 73.65mu g/mL respectively to human gastric adenocarcinoma cell line SGC-7901 and human hepatoma cell Hep G2; and the IC50 value of the anti-herpes simplex HSV-I virus is 30.68mu g/mL.

The invention discloses an ursolic acid pyrimidine amide derivative as well as a preparation method and application thereof, and belongs to the technical field of organic synthesis and medicinal chemistry. The structural formula of the ursolic acid pyrimidine amide derivative is as shown in formula I. The preparation of the ursolic acid pyrimidine amide derivative comprises the following steps: oxidizing C-3 hydroxyl on an ursolic acid A ring into carbonyl, reacting with benzaldehyde with different substituent groups to obtain a benzylidene ursolic acid derivative, and reacting with different amines under the action of DCC/HOBt to generate an amide group, and reacting the ursolic acid amide derivative with guanidine hydrochloride in an alkaline environment to obtain the finished compound. The compound has a remarkable inhibition effect on human lung cancer cells A549, human breast cancer cells MCF-7, human cervical cancer cells HeLa and human hepatoma cell lines Hep G2, shows low toxicity on human normal hepatic epithelial cells Ges-1, and has the potential of developing and preparing antitumor drugs.

The invention provides a composition containing orlistat and dihydropyrimidine compounds. The specific definition of the dihydropyrimidine compounds is shown in the specification. The in-vitro test result indicates that the orlistat and dihydropyrimidine compounds can generate a synergistic inhibiting action on HBV (hepatitis B virus) DNA (deoxyribonucleic acid) replication in Hep G2.2.15 cells within the mol ratio range (the combined drug index CI is less than 1).

The invention relates to an antitumor drug which benzotriazole compounds. The antitumor drug has the advantages that the compounds have a good proliferation inhibition effect on human hepatocellular carcinoma cell lines Hep G2 and Hep 3B, and human gastric cancer cell lines SGC-7901 and HS-746T, and the proliferation inhibition is not inferior to sorafenib; part of compounds even have far more inhibitory activity than the sorafenib; the antitumor drug can be used for treating various cancers, especially liver cancer and stomach cancer.